Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.

Löwenberg, Bob; Pabst, Thomas; Maertens, Johan; Gradowska, Patrycja; Biemond, Bart J; Spertini, Olivier; Vellenga, Edo; Griskevicius, Laimonas; Tick, Lidwine W; Jongen-Lavrencic, Mojca; van Marwijk Kooy, Marinus; Vekemans, Marie-Christiane; van der Velden, Walter J F M; Beverloo, Berna; Michaux, Lucienne; Graux, Carlos; Deeren, Dries; de Weerdt, Okke; van Esser, Joost W J; Bargetzi, Mario; ... (2021). Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood advances, 5(4), pp. 1110-1121. American Society of Hematology 10.1182/bloodadvances.2020003855

[img] Text
advancesadv2020003855.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly diagnosed patients age 18 to 65 years with AML: idarubicine-cytarabine (cycle 1) and daunorubicin and intermediate-dose cytarabine (cycle 2) without or with lenalidomide (15 mg orally on days 1-21). One final consolidation cycle of chemotherapy or autologous stem cell transplantation (auto-SCT) or allogeneic SCT (allo-SCT) was provided according to a prognostic risk and minimal residual disease (MRD)-adapted approach. Event-free survival (EFS; primary end point) and other clinical end points were assessed. A second random assignment in patients in complete response or in complete response with incomplete hematologic recovery after cycle 3 or auto-SCT involved 6 cycles of maintenance with lenalidomide (10 mg on days 1-21) or observation. In all, 392 patients were randomly assigned to the control group, and 388 patients were randomly assigned to lenalidomide induction. At a median follow-up of 41 months, the study revealed no differences in outcome between the treatments (EFS, 44% ± 2% standard error and overall survival, 54% ± 2% at 4 years for both arms) although in an exploratory post hoc analysis, a lenalidomide benefit was suggested in SRSF2-mutant AML. In relation to the previous Dutch-Belgian Hemato-Oncology Cooperative Group and Swiss Group for Clinical Cancer Research (HOVON-SAKK) studies that used a similar 3-cycle regimen but did not pursue an MRD-guided approach, these survival estimates compare markedly more favorably. MRD status after cycle 2 lost prognostic value in intermediate-risk AML in the risk-adjusted treatment context. Maintenance with lenalidomide showed no apparent effect on relapse probability in 88 patients randomly assigned for this part of the study.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Pabst, Thomas Niklaus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2473-9529

Publisher:

American Society of Hematology

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

27 Sep 2021 11:34

Last Modified:

27 Sep 2021 11:34

Publisher DOI:

10.1182/bloodadvances.2020003855

PubMed ID:

33616652

BORIS DOI:

10.48350/159228

URI:

https://boris.unibe.ch/id/eprint/159228

Actions (login required)

Edit item Edit item
Provide Feedback